Franklin Resources Inc. Has $459.81 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Franklin Resources Inc. lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,668,130 shares of the medical equipment provider’s stock after selling 5,730 shares during the quarter. Franklin Resources Inc. owned 2.36% of Zimmer Biomet worth $459,811,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ZBH. Vanguard Group Inc. raised its stake in shares of Zimmer Biomet by 0.9% in the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after purchasing an additional 198,370 shares in the last quarter. Dodge & Cox boosted its stake in Zimmer Biomet by 12.9% during the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after buying an additional 2,533,009 shares in the last quarter. Capital International Investors boosted its stake in Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares in the last quarter. American Century Companies Inc. increased its holdings in Zimmer Biomet by 8.7% in the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after buying an additional 458,903 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Zimmer Biomet by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after buying an additional 69,485 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of analyst reports. Citigroup reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. William Blair assumed coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They issued a “market perform” rating for the company. Barclays cut their price target on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research note on Thursday, February 12th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $94.00 to $120.00 in a report on Monday, January 5th. Finally, Sanford C. Bernstein upped their price objective on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Stock Up 2.3%

ZBH opened at $93.82 on Thursday. The firm’s 50-day simple moving average is $92.28 and its 200-day simple moving average is $95.40. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The firm has a market cap of $18.36 billion, a price-to-earnings ratio of 26.50, a PEG ratio of 1.87 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the firm posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.